Topic tacrolimus, alternative treatment for oral erosive lichen planus resistant to steroids : a case report by Riaño Argüelles, A. et al.
E462
 Oral Medicine and Pathology                                                                                                                                                                                                                 Med Oral Patol Oral Cir Bucal 2006;11:E462-6.                                                      Oral Medicine and Pathology                                                                                     � Med Oral Patol Oral Cir Bucal 2006;11:E462-6.
Topic tacrolimus, alternative treatment for oral erosive lichen planus 
resistant to steroids: A case report
Ana Riaño Argüelles 1, Raúl Martino Gorbea 2, María Eugenia Iglesias Zamora 3, Joaquín Garatea Crelgo 2 
 
(1) Medical Assistant. Maxillofacial Surgery. Virgen del Camino Hospital
(2) Maxillofacial Surgeon. Virgen del Camino Hospital
(3) Dermatologist. Navarra Hospital. Pamplona 
Correspondence:
Dra. Ana Riaño Argüelles
Plaza Rafael Alberti nº 9 1º C 




Riaño-Argüelles A, Martino-Gorbea R, Iglesias-Zamora ME, Garatea-
Crelgo J.Topic tacrolimus, alternative treatment for oral erosive lichen 
planus resistant to steroids: A case report. Med Oral Patol Oral Cir 
Bucal 2006;11:E462-6.
© Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946
ABSTRACT
The lichen planus is a mucocutaneous disease with unknown etiology and auto-immune pathogenia. There have been 
three variants of lichen planus: the reticular, the plaque-like and the atrophic-erosive lesions. It’s a chronic disease with 
acute relapses that generally affects more frecuently to women from the fourties. The diagnostic is based on the clinic 
identification of the lesions joined with the histopathologic study (basal cells hidropic degeneration, linfoplasmocitic 
infiltration and absence of displasy signs). The great number of therapeutic options are explained for its high prevalency 
(0.5-2%), its recurrence and its risk for malignant transformation. 
We present a case of oral erosive lichen planus, refractory to numerous treatments, mainly corticosteroids. During 15 days 
the lesion responded to the administration of  a 0.1% tacrolimus in topic application. This article tries to show the new 
indication of tacrolimus, a calcineurin inhibitor immunosuppressor, that it is effective in the erosive lesions treatment. 
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RESUMEN
El liquen plano es una enfermedad mucocutánea de etiología desconocida y patogenia autoinmune. Existen tres variantes 
de liquen plano: la forma reticular, la forma en placas y la forma atrófico-erosiva. El curso es crónico con frecuentes 
reactivaciones. Afecta con más frecuencia a mujeres  en la 4ª década de la vida y superiores.  El diagnóstico se basa en 
la identificación clínica de las lesiones junto a el estudio histopatológico (degeneración hidrópica de la capa basal, infil-
trado de linfo-plasmocitario y ausencia de signos de displasia). Su alta prevalencia (0,5-2%), su carácter recurrente y el 
potencial riesgo de transformación maligna explican el gran número de opciones terapéuticas disponibles. 
Presentamos un caso de liquen plano erosivo, de mucosa oral, resistente a múltiples tratamientos, fundamentalmente 
corticoideos. En el plazo de 15 días respondió a la administración de  tacrolimus al 0,1% en aplicación tópica. El artículo 
pretende señalar la indicación novedosa del principio activo tacrolimus, un inmunosupresor inhibidor de la calcineurina, 
que se ha demostrado eficaz en la solución de  las lesiones erosivas.
Palabras clave: Liquen plano erosivo oral, tacrolimus tópico oral.
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INTRODUCTION
The lichen planus is a chronic disorder with unknown 
etiology that affects from 0.5 to 2% of the population (1). 
It frequently appears in patients in the age range from 30 
to 70 years old. In 52 for 80% of the cases these patients 
are women (2). 
Its pathogenia is autoimmune mediated for T-cells that 
attacks the mucosa basal cells and/or skin by retarded hy-
persensibility mechanism (1).
The oral form is more frecuently, resistant and persistent 
than the cutaneous one. The main oral localizations are the 
buccal mucosa, tongue and joined gum. There are  three 
recognized varieties of lichen planus that, according to an 
increased order in gravity and symptomatology, are: the 
reticular, the plaque-like and the atrophic-erosive lesions. 
The classic therapeutic management of erosive lichen planus 
is based on the topic application or intralesional injection 
of corticosteroids. As immunosuppressor agent is also used 
cyclosporine. Other alternatives to the treatment are creams 
based on retinoids (vitamin A), anti inflammatories o antipru-
ritics. Lidocain mouthwashes may numb the area temporarily. 
Ultraviolet light therapy may be beneficial in some cases. 
CLINICAL CASE
Patient, woman, 68 years old. She was remitted to our consul-
tation because she presented two years old ulcerative lesions, 
with reticulated aspect, on the lateral border of the tongue 
(figure 1 and 2). These lesions were very painful and produced 
a weight loss of 10 kg. since she wasn´t able to eat or use her 
dental prosthesis normally. She also had minor ulcerative 
lesions on the superior lip and genital mucosa. The patient, 
as a personal antecedent, had hepatitis C for 12 years old. 
We practised a biopsy over the ulcerative area. The biopsy 
was reported as an unspecified ulcer although it was obser-
ved a band-like linfocitic infiltration, epithelial covered loss 
and ampouled lesion absence in the cuts by congelation. 
The immunofluorescent study resulted negative as well as 
anti-substance intercellular antibodies.  
Based on the clinical aspect of  the lesion, that it had a 
suspected erosive lichen, we started a treatment with topic 
costicosteroids (0,1% triamcinolone acetonide ointment 
2 applications/ 12 hours). No clinical improvement was 
achieved. Then we consulted the case with the Dermato-
logy Department that ratified the clinical diagnosis and, 
using their experience in the treatment of these lesions, they 
decided to establish a therapy with 0.1% topic tacrolimus 
cream, 1 application/day and night. The clinical and ma-
croscopic improvements at 15 days treatment beginning are 
evident (figure 3 and 4).  Because of the good response to 
the treatment, and after many chases in the consultation, it 
was decided to maintain the therapy another month and a 
half, in a continuous way. After this time, another outbreak 
emerged but it was reduced in five days. She remained 
asymptomatic throughout the three-month period. 
However, the patient didn’t tolerate the 0.1% tacrolimus 
treatment on her genital lesions and it was necessary to 
reduce the posology to the 0.03% tacrolimus. 
Fig. 1. Clinical interview’s frontal view. Note to lower 
lip and both tongue borders affectation.
Fi. 2. Right lateral view where we can observe the ulce-
rative and reticulate description of the lesions.
Fig. 3. Frontal view after 15 days of  topic 
tacrolimus treatment.
Fig. 4. Right lateral view after 15 days of topic 
tacrolimus treatment; the clinical improvement 
is evident.
E464
 Oral Medicine and Pathology                                                                                                                                                                                                                 Med Oral Patol Oral Cir Bucal 2006;11:E462-6.                                                      Oral Medicine and Pathology                                                                                     � Med Oral Patol Oral Cir Bucal 2006;11:E462-6.
DISCUSSION
The patients affected for lichen planus frecuently exceed 
the 40 years old and, according to clinical studies, from 50 
to 80% of the cases are women (2). The more frecuently 
localizations are buccal mucosa, tongue and joined gum (in 
its vestibular way).  As predisposed factors of lichen planus 
there were implicated numerous associations of histocompa-
tibility antigens, mainly the HLA-DR type that produced a 
more intense band-like infiltration (2).  The symptoms are 
increased with emotional stress, chemicals or medications 
including (gold, non steroid anti-inflammatories) and many 
others. 
The most accepted pathogenic mechanism is based on the 
basal cell induction by unknown factors (tissular damage, 
drugs, γ interferon produced by non-specific activated lym-
phocytes …). After this stimulus, the basal cells start a class 
II antigen production (type HLA-DR), that normally they 
don’t have interacting with lymphocytes as a Langerhans 
cell. In this way a cell mediated autoimmunity reaction is 
started (3). The immunopathogenic hypothesis achieved 
great importance when we discover a frequently association 
between lichen planus and other autoimmune processes 
(myasthenia gravis, Sjögren syndrome, ulcerous colitis…).
Likewise it has been described cases of association between 
lichen planus and hepatic diseases, in some cases with he-
patitis C, even though it doesn’t exist a significant statistic 
correlation (3). Although the viral genome in the epithelium 
of the patients affected for lichen planus can’t be detected, 
it seems to act as indirect way altering the percentage of 
lymphokynes (increases the percentage of  TNF-α and 
reduced the IL-1, INF-γ e IL-8) (4). 
Recent studies (5) explain the relation between the psycho-
logical situation of the patient and the lichen planus lesions, 
that is usually observed in the daily clinical practice. When 
a psychological alteration is present, a significant stadistic 
increased number of linfocites T CD4+ exists, joined to a 
high tendency of suffering atrophic-erosive lesions. Accor-
ding to this study, it can be suggested a pathogenic model 
in which the psychological alteration produced an impact 
over the neuroendocrinous system, that would influence 
over the linfocites subpopulations. 
Some authors describe a possible implication of the lipid 
metabolism in the pathogenia and evolution of the oral 
lichen planus lesions, since there are significant stadistic di-
fferences in the cholesterol and VLDL rates between patients 
suffering lichen planus and healthy volunteers (6). 
The erosive form, case of this article, is the variant with more 
symtomatology and the second in order of frequency behind 
the reticular form. It produces ulcers over a erythematosus 
lesion with some hyperkeratosis focus. Due to the mucosa 
basal cells destruction it is possible to find blister formation 
and the appearance of Nikolsky + sign. Our patient explai-
ned a regular descamative evolution of her lesions, perhaps 
due to this failure in the basal cells support.    
The diagnosis is clinic and it must be confirmed by biopsy. 
The biopsy will be more significative if  it is done in an 
eritematous zone instead of  in the nucleus of  the ulcer, 
because the epithelial layers have been lost in this area and 
a secondary inflammation is existed. The histologic study 
of the biopsy will observe a superficial and fine epithelium 
joined to a connective tissue thanks to a fine basal layer that 
shows hydropic degeneration because of the cytotoxic effect 
of the T cells over the basal cells. These fine epithelium areas 
alternate with others, denudated, where the epithelium has 
disappeared and it only has seen a vascular connective tissue 
and a profuse inflammatory infiltrated of lympho-plasmo-
cytic cells (7). The immunofluorescence isn’t useful in these 
cases because it hasn’t been implicated auto antibodies. 
It’s necessary to realize a differential diagnosis between the 
erosive form and the erythroplasia as a clinic translation 
of a dysplasia. The lichen planus has been considered as 
a premalignant lesion. The malignant transformation into 
a squamous carcinoma occurs from 1 to 3 % of the cases, 
above all when the lesion is located on the tongue. Other si-
milar diseases are: penphigoid, pemphigus vulgaris, chronic 
ulcerative stomatitis and even chronic candidiasis (8).  
The treatment of this pathology is varied. The principal goal 
is to reduce the symptoms and secondary the total o partial 
extinction of the lesion.  Although traditional treatment is 
based on immunosuppressor therapy with topic or injected 
corticosteroids on the lesion, there isn’t a main therapeutic 
group because of the variety in the response of each patient. 
Other treatment options are the cyclosporine, vitamin A 
analogues, topic anti-inflammatories applications. Unders-
tanding the pathogeny it’s easy to understand the high rate 
of recurrence of this disease.  
In lesions resistant to this conventional therapy, as is 
this case, it has been described the benefits of 0.1% topic 
tacrolimus. The posology varies from one to four times a day 
(9-11) according to different studies. Tacrolimus is caused 
by the Streptomyces tsukubaensis (12) and belongs to the 
macrolid family. It has an immunosuppressor action similar 
to the cyclosporine although it penetrates deeply on the 
mucosa and it’s from 10 to 100 times more potent that this 
(1). It inhibits the first step of the T lymphocytes activation, 
since it fixes to the immunophilin, the FKBPB 12, forming 
a complex inhibitor to the calcineurin’s phosphatase. This 
enzyme catalyses a critic un-phosphorilation for the trans-
cription of various lymphokynes (IL-2, IL-3, IL-4…). These 
cytokines activate the T and B lymphocytes. When the levels 
of  T cells activators decrease proliferation answer’s cells 
against the antigens and mitogens also decreased. 
 The topic tacrolimus is an active principle of proved efficacy 
in the resistant atopic dermatitis treatment. Recently it’s 
used for lichenoid lesions in oral topic way although this 
application isn’t recognized by the fabricant. In this sense, 
tacrolimus must be prescribed as a “compassionate use” 
standing for the use of a drug in a few patients, for new 
indications, without a clinical test when the doctor considers 
essential its use.  
The symptoms decrease in the first month of tacrolimus 
treatment. The recurrences start form 6 to 12 months after 
the suspension of treatment although these cases seem to 
be less resistant to the conventional therapy. If  we look 
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up different  studies about efficacy and security of long 
tacrolimus treatment (9), we can conclude that after the 
0.1% tacrolimus application twice a day during 8 weeks 
a 94% of  the patients experiment clinical improvement. 
Although during the first 8 weeks, an optimal control of 
the syntomathology is achieved, it’s necessary to continue 
with the treatment, in an intermittent way, to achieve the 
remission. Tacrolimus treatment is revealed as an effective 
and secure alternative due to its low systemic absorption 
(9) and the low incidence and importance of its secondary 
effects.  Among the undesirable effects, we must mention the 
burning sensation on the application area (16%), transitory 
alteration of taste (8%) and reverse pigmentation of the 
treaty area (due to an increase in the melanocytes number 
and the melanogenesis) (9, 13). The unique effect  not related 
to the application site is the intermittent migraine in the 4% 
of the treated patients (9).  A lot of secondary effects, that 
not exceed  the 1% of frequency, can be related to the skin 
application /alopecia, ALT and AST increased, anaphylactic 
reaction, pneumonia, depression…). 
Several publications associate the topic tacrolimus treatment 
with an increased risk of lymfoproliferative disorders or 
skin tumours. Taking into account the information from the 
pharmacological industry (protopic®), the existence of ani-
mal studies in this matter is checked. A carcinogenetic study 
of dermal effect of 0,03 to 3% of tacrolimus over mousses 
during 104 weeks, concluded that there aren’t statistical 
differences in the skin tumour incidence but in pleomorphic 
lymphoma and skin undifferentiated tumours, when the 
application doses are maximum.  There aren’t studies about 
the effects over pregnancy or lactation although it’s known 
that tacrolimus goes through the placenta and maternal 
milk, causing hypercalcemia and renal dysfunction in the 
foetus.  Its use in these patients must be clinically justified 
and it must be sure that the benefits surpass the potential 
foetus risk (14).  
Recent articles (12) are in favour of the pimecrolimus use 
belonging to the same family of the tacrolimus but it has a 
less firm union to the FKBPB 12 protein than the second. 
For this reason, the burning sensation is minor than the 
tacrolimus one. The use of photodynamic therapy to the oral 
lichen planus is more recent. It consists in the application 
of methylene blue into the lesion. Secondary the inflam-
matory cells pick up it and then it’s applied a determinate 
wave length over the lesion that induces an apoptosis of 
these cells (15).  
Therefore, in a high prevalent pathology such as lichen pl-
anus with potential malignant transformation, tacrolimus 
can be offered as an alternative, safety and secure therapy 
to be considered when the lesions are resistant to the con-
ventional treatment. 
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